Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc's stock outlook is supported by favorable data from the Phase 2b RewinD-LB trial for its product candidate, Neflamapimod, particularly highlighted by a 64% risk reduction (p=0.0001) among patients with minimal evidence of Alzheimer's disease co-pathology. The trial's 32-week open-label extension produced significant results, showcasing Neflamapimod's potential to treat synaptic dysfunction associated with age-related neurologic disorders. Additionally, the contrasting results of placebo recipients, who exhibited a mean increase in biomarkers, further underscore the effectiveness of Neflamapimod in this patient population.

Bears say

CervoMed Inc faces multiple significant risks that contribute to a negative outlook on its stock, including the potential inability to establish a clinically acceptable development pathway for its lead product candidate, neflamapimod, in treating dementia with Lewy bodies (DLB). Additionally, the company confronts challenges related to the generation of positive data from pivotal clinical trials, which could hinder regulatory approval and market uptake, alongside risk of dilution in the medium term. The valuation methodology applied, incorporating a 40% probability of approval for neflamapimod, coupled with a high discount rate of 12%, reflects substantial uncertainty regarding the product's future success in the market.

CervoMed Inc (CRVO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.